Spectral Medical Provides February Tigris Trial Update

Core Insights - Spectral Medical Inc. is advancing its Tigris trial, a Phase 3 study evaluating Polymyxin B Hemoperfusion (PMX) for treating endotoxemia and septic shock [2][4] - The company aims to finalize full enrollment of 150 evaluable patients by the end of March 2025, with 152 patients already enrolled [8] Enrollment Update - As of now, 152 patients have been enrolled in the Tigris trial, with six patients enrolled in February [8] - The trial is designed to randomize 150 patients in a 2:1 ratio, with 100 patients receiving PMX and 50 receiving standard care [6][8] - The company estimates that an additional four to seven patients are needed to reach the target of 150 evaluable patients [8] Product and Market Context - PMX is already approved for therapeutic use in Japan and Europe, having been safely used on over 340,000 patients [5] - Approximately 330,000 patients are diagnosed with septic shock annually in North America, highlighting the market potential for PMX [5]